What Is Behind China's 'Zero-COVID'? Money-Making Machines And Business Interest Chains
Storm looms over China's fastest-growing health sector
Executive Summary
One well-connected individual registered as many as 35 nucleic testing firms within just a few months, all of which are strategically located in the Chinese cities that have seen some of the worst COVID-19 flareups. Meanwhile, regulators have halted the IPOs of 13 companies.
You may also be interested in...
Cold Water On Already Frozen Sector: Industry Growing Wary Of China Price Cuts
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.
China's Shrinking Population Poses New Challenge For Pharma
For the first time in 61 years, China has reported its population is shrinking and the new demographic shift is likely to have a far-reaching impact on the pharma sector. Meanwhile, regulators have accelerated the approval of new COVID-19 drugs to relieve acute shortages.
Big Antibody Deals Offer Hope Amid Challenging Times For China Biotech
Recent antibody mega-deals are providing a rare bright spot for the embattled China biotech sector, amid sharply rising COVID-19 deaths in the country that indicate rebound and recovery could take longer than previously expected.